Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Cancer shared this article with you from Inoreader Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL Via MedWorm Cancer & Oncology Clinical Trials Condition:   Lymphoma, Non-Hodgkin Intervention:   Biological: anti-CD19 FasT CAR-T cells Sponsors:   Xinqiao Hospital of Chongqing;   Gracell Biotechnologies (Shanghai) Co., Ltd;   920th Hospital of Joint Logistics Support Force;   The Second Affiliated Hospital of Chongqing Medical University;   The Affiliated Hospital Of Guizhou Medical University;   The Second Affiliated Ho spital of Kunming Medical University;   Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.